Teva's Stock Surges as It Eyes Inclusion in S&P 500 Following Strong Q2 Results
Teva Pharmaceutical Industries saw a sharp rise in its stock price on Wednesday after reporting strong second-quarter results, pushing its market value above $40 billion and delivering over 100% returns since the start of the year. This surge has sparked discussions within the company about the possibility of joining the prestigious American S&P 500 index. Under CEO Richard Francis, Teva has transformed from a generic drug giant into a profitable original drug manufacturer, earning investor confidence and trading at price-to-earnings multiples comparable to major innovative pharmaceutical companies like Pfizer and Sanofi.
The company recently upgraded its credit rating to investment grade for the first time in over a decade, attracting renewed interest from international investors. Teva plans to complete a direct listing of its shares on the New York Stock Exchange by September 14, moving away from its current trading via American Depositary Shares (ADS), which has limited some institutional investors and complicated index inclusion. CFO Eli Kalif indicated that after the direct listing, Teva could join the Russell 1000 index and potentially the S&P 500 if its market value continues to grow.
Teva’s shift is reflected in its financials: for the first time, its three main original drugs generated combined quarterly revenues exceeding $1 billion, growing 43% year-over-year. Key products include Otezla for inflammatory bowel diseases, Ajovy for migraines, and the new schizophrenia drug, Vraylar. The company also holds a promising pipeline of five advanced-stage drugs and a biosimilar portfolio expected to nearly double in the coming years. Growth in original drugs offset a 15% decline in generics, partly due to the end of revenues from a generic version of Revlimid.
The acquisition of Amneal Pharmaceuticals for $700 million, completed in June, temporarily impacted profitability due to a one-time $726 million accounting expense, resulting in an operating loss of $231 million and a net loss of $576 million for the quarter. However, adjusted earnings per share were 2 cents, and cash flow remained strong at $622 million. Teva is also working to sell its raw materials division, TAPI, which is not central to its strategic focus.
Despite the temporary hit to profits, Teva maintained its full-year guidance, expecting revenues between $16.5 billion and $16.85 billion, adjusted operating profit of $3.8 billion to $4 billion, and free cash flow of $2 billion to $2.4 billion. The company’s strategic moves and financial performance have positioned it well for further growth and potential inclusion in major U.S. stock indices.
